gip glp 1 agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GIP Receptor Agonism Attenuates GLP-1
Description
You cannot tolerate GI side effects
Achieving a healthier weight can decrease the risk of complications associated with obesity, such as diabetes, fatty liver disease, sleep apnea, heart disease, depression, joint pain, and certain cancers
Contract development and manufacturing organizations (CDMOs) have rapidly expanded peptide synthesis capabilities to capture the GLP-1 opportunity
The availability of appropriate insurance may provide a future challenge to expanding the market for glucagon-like peptide 1 (GLP-1) agonists
